Dr. Martens’ (DOCS) Sector perform Rating Reaffirmed at Royal Bank Of Canada

Dr. Martens (LON:DOCS)‘s stock had its “sector perform” rating reaffirmed by analysts at Royal Bank Of Canada in a research note issued on Tuesday,Digital Look reports. They currently have a GBX 100 target price on the stock. Royal Bank Of Canada’s price target points to a potential upside of 49.81% from the company’s current price.

Several other brokerages have also recently weighed in on DOCS. Peel Hunt reiterated a “buy” rating on shares of Dr. Martens in a research report on Thursday, November 20th. Berenberg Bank reiterated a “buy” rating on shares of Dr. Martens in a research note on Tuesday, January 27th. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of GBX 100.

Dr. Martens Stock Down 1.0%

Shares of DOCS stock opened at GBX 66.75 on Tuesday. The stock’s fifty day moving average price is GBX 75.55 and its 200 day moving average price is GBX 83.06. The company has a debt-to-equity ratio of 127.27, a current ratio of 2.85 and a quick ratio of 1.13. Dr. Martens has a 1-year low of GBX 43.02 and a 1-year high of GBX 100.87. The company has a market cap of £645.18 million, a price-to-earnings ratio of 39.26, a price-to-earnings-growth ratio of 6.40 and a beta of 0.11.

Dr. Martens (LON:DOCS) last issued its quarterly earnings results on Thursday, November 20th. The company reported GBX (0.90) earnings per share for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. On average, research analysts expect that Dr. Martens will post 2.5809394 earnings per share for the current fiscal year.

Insider Buying and Selling at Dr. Martens

In related news, insider Robert Hanson bought 96,000 shares of the stock in a transaction that occurred on Friday, December 5th. The stock was purchased at an average cost of GBX 79 per share, for a total transaction of £75,840. In the last 90 days, insiders have bought 97,130 shares of company stock worth $7,673,816. Corporate insiders own 2.79% of the company’s stock.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.